DOCSLIB.ORG

High Risk Medications in the Elderly (Age≥65) and Suggested Alternatives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
High Risk Medications in the Elderly (Age≥65) and Suggested Alternatives High Risk Medications in the Elderly (Age≥65) and Suggested Alternatives The medications listed below reflect the most recent High Risk Medication (HRM) list, developed and endorsed by the Pharmacy Quality Alliance (PQA) in June 2012. The safer treatment options provided represent potential alternatives to HRMs. Providers should evaluate whether these alternatives can be used in place of HRMs for their patients. Therapeutic Class High Risk Medications Potential Risks Safer Treatment Options† First Generation - Brompheniramine Elderly patients are more For Allergic Rhinitis: Levocetirizine, Desloratadine, Antihistamines1,2,3 - Carbinoxamine (Arbinoxa, Palgic) susceptible to anticholinergic Azelastine (nasal), Fluticasone (nasal), Flunisolide (nasal), and - Chlorpheniramine adverse events including urine Nasonex - Clemastine retention, confusion, and sedation. For N/V: Ondansetron (QL = 90/30) - Cyproheptadine For Pruritus: Ammonium lactate, Levocetirizine, Desloratadine, - Dexbrompheniramine Topical steroids - Dexchlorpheniramine For Anxiety: SSRIs, buspirone, venlafaxine - Diphenhydramine (Benadryl) In addition, there are OTC Options for which coverage may vary - Doxylamine (Doxytex) depending on benefit plan design: - Hydroxyzine (Vistaril) - Cetirizine (Zyrtec), Loratadine (Claritin), Fexofenadine (Allegra) - Promethazine (Phenergan) - Triprolidine - All combination products containing one of these medications Skeletal Muscle - Carisoprodol (Soma) Most muscle relaxants are poorly For Spasticity: Baclofen, Tizanidine, and Dantrolene 1,2,4 Relaxants - Cyclobenzaprine (Flexeril) tolerated in the elderly due to anti- : oral NSAIDs*, Voltaren gel, Cymbalta; - Methocarbamol (Robaxin) cholinergic effects, sedation and For Muscluloskeletal Pain May consider non-pharmacologic treatments, such as cryotherapy, - Orphenadrine (Norflex) cognitive impairment. In addition, heat, massage, stretching/exercise, and transcutaneous electrical - Metaxalone (Skelaxin) these agents have abuse potential. nerve stimulation (TENS) - Chlorzoxazone (Parafon Forte) - All combination products containing * Gastroprotective therapy with a PPI recommended in chronic NSAID use one of these medications Non-Narcotic - Indomethacin Among available NSAIDs, For Moderate to Severe Pain: Other NSAIDs*, Tramadol, 1,2 Analgesics - Ketorolac (Toradol) indomethacin produces the highest Hydrocodone/ acetaminophen, Oxycodone/acetaminophen - Ketorolac nasal (Sprix) rates of CNS adverse events, including confusion and (rarely) * Gastroprotective therapy with a PPI recommended in chronic NSAID use psychosis. Ketorolac is associated with a high risk of GI bleeds in the elderly. Narcotic - Meperidine (Demerol) These specific medications are less For Moderate Pain: NSAIDs*, Tramadol, Hydrocodone/APAP, 1,2 Analgesics - Pentazocine / APAP (Talacen) effective than other narcotics and APAP with codeine - Pentazocine / naloxone (Talwin NX) have more CNS adverse effects For Severe Pain: Oxycodone, Oxycodone/APAP, Hydromorphone, such as confusion and hallucina- Morphine tions. Also, their use increases the risk of falls and seizures. * Gastroprotective therapy with a PPI recommended in chronic NSAID use Progestins1,2,5 - Megestrol (Megace, Megace ES) Megestrol is substantially excreted - Medroxyprogesterone by the kidney. Because elderly - Dronabinol patients are more likely to have decreased renal function, there is an increased risk of toxicity, including adrenal suppression and thrombosis. † Treatment alternatives may require prior authorization or step therapy. For the most current formulary listings, please consult: http://www.myhealthspring.com/formularies, or http://www.mybravohealth.com/formulary. 1 High Risk Medications in the Elderly (Age≥65) and Suggested Alternatives Therapeutic Class High Risk Medications Potential Risks Safer Treatment Options† Estrogens and - Conjugated estrogen (Premarin) Elderly patients on long-term oral For Hot Flashes: Estrogen / - Conjugated estrogen / medroxy- estrogens are at increased risk for Continuously re-evaluate the need for long-term estrogen therapy; Progesterone progesterone (Prempro, Premphase) breast and endometrial cancer. In evaluate non-drug therapy. Postmenopausal women should avoid Products (Oral and - Estradiol, oral (Estrace, Femtrace) addition, results from the Women’s using oral estrogens for more than 3 years. After 3 years patients 1,2,6 Transdermal) - Estradiol patch (Alora, Climara, Health Initiative (WHI) hormone should be titrated off therapy due to the risks outweighing the Estraderm, Estradiol, Menostar, trial suggest these medications benefits. Vivelle-Dot) may increase the risk of heart SSRIs, Gabapentin, and Venlafaxine have non-FDA labeled - Estradiol / drospirenone (Angeliq) attack, stroke, blood clots, and indications (medically accepted use) for hot flashes. - Estradiol / levonorgestrel dementia. For Vaginal Symptoms: Premarin Cream, Estring, Femring, (ClimaraPro) Vagifem - Estradiol / norethindrone (CombiPatch) For Bone Density: Alendronate, Actonel, Atelvia, Evista, Prolia - Estradiol / norgestimate (Prefest) - Estropipate (Ogen, Ortho-Est) - Esterified estrogen (Menest) - Esterified estrogen / methyltestosterone (Covaryx, Estratest) - Ethinyl estradiol / norethindrone (Activella, FemHRT) Urinary Anti- Greater than 90 days cumulative Nitrofurantoin is substantially For treatment of acute UTI: Ciprofloxacin, Trimethoprim / 1,2,7 Infectives supply during the plan year: excreted by the kidney. Since sulfamethoxazole (TMP/SMX), Amoxicillin/clavulanate, Cefdinir, - Nitrofurantoin (Furadantin) elderly patients are more likely to Cefaclor, Cefpodoxime, Suprax - Nitrofurantoin monohydrate/ have decreased renal function, macrocrystals (Macrobid) nitrofurantoin use is associated For prevention of recurrent UTIs: - Nitrofurantoin macrocrystals with an increased risk of pulmonary Prescription options include: TMP/SMX, Methenamine hippurate (Macrodantin) toxicity, neuropathy, and hepato- toxicity. In addition, there is a lack Non-prescription options include practicing good personal hygiene, of efficacy in patients with a CrCl avoiding baths, and wearing cotton underwear. <60 mL/min due to inadequate drug concentration in the urine. Anti-emetics1,2 - Promethazine Elderly patients are more For N/V: Ondansetron (QL = 90/30) - Trimethobenzamide (Tigan) susceptible to anticholinergic adverse events including urine retention, confusion, and sedation. Anti-Anxiety - Meprobamate Meprobamate has a high risk of - Buspirone Agents1,2 abuse, and is highly sedating. Use in the elderly may result in - SSRIs (Fluoxetine, Citalopram, Paroxetine) confusion, falls/fractures,and - SNRIs (Venlafaxine, Cymbalta) respiratory depression. Alpha-Blockers, - Guanabenz May cause bradycardia, sedation, - ACE inhibitors / ARBs 1,2 Central - Guanfacine orthostatic hypotension, and - Beta-blockers exacerbate depression. - Methyldopa - Calcium channel blockers - Reserpine (>0.1 mg/day) - Thiazide diuretics † Treatment alternatives may require prior authorization or step therapy. For the most current formulary listings, please consult: http://www.myhealthspring.com/formularies, or http://www.mybravohealth.com/formulary. 2 High Risk Medications in the Elderly (Age≥65) and Suggested Alternatives Therapeutic Class High Risk Medications Potential Risks Safer Treatment Options† Calcium Channel - Nifedipine immediate-release Immediate release nifedipine may - Amlodipine, Felodipine, Isradipine, Nicardipine, Nisoldipine 1,2 Blockers (Adalat, Procardia) cause excessive hypotension and - Extended-release Nifedipine constipation in the elderly. Cardiovascular, - Disopyramide Disopyramide may induce heart - For disopyramide: Beta-blockers, Calcium channel blockers, 1,2 Other - Digoxin (>0.125 mg/day) failure in elderly patients. It is also Flecainide strongly anticholinergic, and may cause urine retention, confusion, - For digoxin > 0.125 mg/day: In heart failure, digoxin dosages and sedation. >0.125 mg/day have been associated with no additional benefit and may have increased toxic effects. Digoxin is substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, there is an increased risk of toxicity at doses exceeding 0.125 mg/day. Sedative - Chloral hydrate Impaired motor and/or cognitive Consider non-pharmacologic interventions, focusing on proper sleep Hypnotics1,2 performance after repeated hygiene. When sedative hypnotic medications are deemed clinically Greater than 90 days cumulative exposure. necessary, use should be at the lowest possible dose for the supply during plan year: shortest possible time. - Eszopiclone (Lunesta) Rozerem may be considered as a safer option - Zolpidem (Ambien, Ambien CR) with less abuse potential. - Zaleplon (Sonata) 1,2 Barbiturates - Phenobarbital (Luminal) These medications are highly PLEASE NOTE: Patients being switched off barbiturates should (Currently covered if - Mephobarbital (Mebaral) addictive and cause more adverse be tapered slowly over a prolonged period of time. used in the treatment - Secobarbital (Seconal) effects than most other sedatives in For seizures: Divalproex, Levetiracetam, Lamotrigine, of epilepsy, cancer, or - Butabarbital (Butisol) the elderly, greatly increasing Carbamazepine a chronic mental health - Pentobarbital (Nembutal) cognitive impairment, confusion, 8 For sleep: Consider non-pharmacologic interventions, focusing on disorder.) - Butalbital and Butalbital and risk of falls. proper sleep hygiene. When sedative hypnotic medications
Load more

Recommended publications
  • Asthma/COPD Agents
    Quick Reference Drug List: Asthma/COPD Agents each State Health Plan has compiled a list of available products used to treat this condition. This reference will help identify preferred products, in addition to some P limitations or step-therapies when a product requires a prior authorization. Any non-PDL product will require the trial and failure of two PDL agents be documented on a prior authorization review. Generic products are preferred. Prior Authorizations should be sent to Envolve Pharmacy Solutions: Prior Authorization Phone: 866-399-0928 Prior Authorization Fax: 866-399-0929 MEDICAID DRUG INGREDIENT DOSAGE PDL LIMITS & NAME FORM/STRENGTH STATUS RESTRICTIONS Short Acting Beta Adrenergic Agonists (SABA) Albuterol Albuterol Sulfate Neb Sol: 0.63 mg/3ml, Yes QL: 375ml per 30 Sulfate 1.25mg/3ml, 0.083% day (0.63mg/3ml and (2.5mg/3ml), 0.5% 1/25mg/3ml only); (2.5mg/0.5ml) QL: 12.5 ml per day Syr: 2 mg/5ml (0.083% only); Tabs: 2mg, 4 mg ER Tabs: 4 mg, 8 mg Alupent® Metaproterenol Syr: 10 mg/5 mL Yes QL: 30ml per day Tabs: 10 mg, 20 mg (syrup only) Brethine® Terbutaline Tabs: 2.5 mg, 5mg Yes None ProAir HFA® Albuterol sulfate Aero sol: 90 mcg/act Yes QL: 8.5gm per fill, 17gm per 30 days ProAir Albuterol sulfate Aero sol: 90 mcg/act Yes AL: At least 4 years Respiclick® old up to 18 years old Proventil Albuterol sulfate Aero sol: 90 mcg/act No PA Required HFA® Ventolin Albuterol Sulfate Aero sol: 90 mcg/act Yes QL: 8gm per fill, HFA® 36gm per 30 days Xopenex® Levalbuterol Neb sol: 0.31mg/3ml, No PA Required 0.63mg/3ml, 1.25mg/0.5ml, 1.25mg/3ml
    [Show full text]
  • Drugs to Avoid in Patients with Dementia
    Detail-Document #240510 -This Detail-Document accompanies the related article published in- PHARMACIST’S LETTER / PRESCRIBER’S LETTER May 2008 ~ Volume 24 ~ Number 240510 Drugs To Avoid in Patients with Dementia Elderly people with dementia often tolerate drugs less favorably than healthy older adults. Reasons include increased sensitivity to certain side effects, difficulty with adhering to drug regimens, and decreased ability to recognize and report adverse events. Elderly adults with dementia are also more prone than healthy older persons to develop drug-induced cognitive impairment.1 Medications with strong anticholinergic (AC) side effects, such as sedating antihistamines, are well- known for causing acute cognitive impairment in people with dementia.1-3 Anticholinergic-like effects, such as urinary retention and dry mouth, have also been identified in drugs not typically associated with major AC side effects (e.g., narcotics, benzodiazepines).3 These drugs are also important causes of acute confusional states. Factors that may determine whether a patient will develop cognitive impairment when exposed to ACs include: 1) total AC load (determined by number of AC drugs and dose of agents utilized), 2) baseline cognitive function, and 3) individual patient pharmacodynamic and pharmacokinetic features (e.g., renal/hepatic function).1 Evidence suggests that impairment of cholinergic transmission plays a key role in the development of Alzheimer’s dementia. Thus, the development of the cholinesterase inhibitors (CIs). When used appropriately, the CIs (donepezil [Aricept], rivastigmine [Exelon], and galantamine [Razadyne, Reminyl in Canada]) may slow the decline of cognitive and functional impairment in people with dementia. In order to achieve maximum therapeutic effect, they ideally should not be used in combination with ACs, agents known to have an opposing mechanism of action.1,2 Roe et al studied AC use in 836 elderly patients.1 Use of ACs was found to be greater in patients with probable dementia than healthy older adults (33% vs.
    [Show full text]
  • Tizanidine Brands: Zanaflex®
    Medication Information Sheet Tizanidine brands: Zanaflex® Medications are only ONE part of a successful treatment plan. They are appropriate when they provide benefit, improve function and have either no or mild, manageable side effects. Importantly, medications (even if natural) are chemical substances not expected in the body, and as such have side effects. Some of the side effects might be unknown. The use of medications/drugs for any purpose requires patient consent. This practice does NOT require a patient to use any medication. Information & potential benefits Tizanidine is a medication that helps with muscle spasms and musculoskeletal pain syndromes; there is evidence that it helps neuropathic and musculoskeletal pain through alpha‐2‐receptor activity. Studies have shown Zanaflex helpful for neuropathic pain and some types of headache. It is currently FDA approved for muscle spasticity. Potential risks and side effects Tizanidine should be used carefully in cases of liver or kidney disease, low blood pressure, or heart conduction problems (QT interval problems). It should not be used with Luvox or with the antibiotic Cipro (ciprofloxacin). There are many other drugs that can interact with Tizanadine. In addition to the standard side effects listed in the disclaimer, common side effects or Zanaflex include dry mouth, sleepiness, dizziness, asthenia, infection, constipation, urinary frequency, flu‐like feeling, low blood pressure, more spasms, sore throat and runny nose. More serious side effects include liver damage, severe slowing of the heart beat and hallucinations. Tizanidine occasionally causes liver injury. In controlled clinical studies, approximately 5% of patients treated with tizanidine had non‐serious elevations of liver function tests.
    [Show full text]
  • Paper Clip—High Risk Medications
    You belong. PAPER CLIP—HIGH RISK MEDICATIONS Description: Some medications may be risky for people over 65 years of age and there may be safer drug choices to treat some conditions. It is recommended that medications are reviewed regularly with your providers/prescriber to ensure patient safety. Condition Treated Current Medication(s)-High Risk Safer Alternatives to Consider Urinary Tract Infections (UTIs), Nitrofurantoin Bactrim (sulfamethoxazole/trimethoprim) or recurrent UTIs, or Prophylaxis (Macrobid, or Macrodantin) Trimpex/Proloprim/Primsol (trimethoprim) Allergies Hydroxyzine (Vistaril, Atarax) Xyzal (Levocetirizine) Anxiety Hydroxyzine (Vistaril, Atarax) Buspar (Buspirone), Paxil (Paroxetine), Effexor (Venlafaxine) Parkinson’s Hydroxyzine (Vistaril, Atarax) Symmetrel (Amantadine), Sinemet (Carbidopa/levodopa), Selegiline (Eldepryl) Motion Sickness Hydroxyzine (Vistaril, Atarax) Antivert (Meclizine) Nausea & Vomiting Hydroxyzine (Vistaril, Atarax) Zofran (Ondansetron) Insomnia Hydroxyzine (Vistaril, Atarax) Ramelteon (Rozerem), Doxepin (Silenor) Chronic Insomnia Eszopiclone (Lunesta) Ramelteon (Rozerem), Doxepin (Silenor) Chronic Insomnia Zolpidem (Ambien) Ramelteon (Rozerem), Doxepin (Silenor) Chronic Insomnia Zaleplon (Sonata) Ramelteon (Rozerem), Doxepin (Silenor) Muscle Relaxants Cyclobenazprine (Flexeril, Amrix) NSAIDs (Ibuprofen, naproxen) or Hydrocodone Codeine Tramadol (Ultram) Baclofen (Lioresal) Tizanidine (Zanaflex) Migraine Prophylaxis Elavil (Amitriptyline) Propranolol (Inderal), Timolol (Blocadren), Topiramate (Topamax),
    [Show full text]
  • CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology
    CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology Generic Name (Brand Name) Cidofovir (Vistide) Acetaminophen/butalbital (Allzital; Citalopram (Celexa) Bupap) Clomipramine (Anafranil) Acetaminophen/butalbital/caffeine Clonidine (Catapres; Kapvay) (Fioricet; Butace) Clorazepate (Tranxene-T) Acetaminophen/butalbital/caffeine/ Clozapine (Clozaril; FazaClo; Versacloz) codeine (Fioricet with codeine) Cyclizine (No Brand Name) Acetaminophen/caffeine (Excedrin) Cyclobenzaprine (Flexeril) Acetaminophen/caffeine/dihydrocodeine Desipramine (Norpramine) (Panlor; Trezix) Desvenlafaxine (Pristiq; Khedezla) Acetaminophen/tramadol (Ultracet) Dexmethylphenidate (Focalin) Aliskiren (Tekturna) Dextroamphetamine (Dexedrine; Amitriptyline (Elavil) ProCentra; Zenzedi) Amitriptyline and chlordiazepoxide Dextroamphetamine and amphetamine (Limbril) (Adderall) Amoxapine (Asendin) Diazepam (Valium; Diastat) Aripiprazole (Abilify) Diethylpropion (No Brand Name) Armodafinil (Nuvigil) Dimenhydrinate (Dramamine) Asenapine (Saphris) Donepezil (Aricept) Aspirin/caffeine (BC Powder; Goody Doripenem (Doribax) Powder) Doxapram (Dopram) Atomoxetine (Strattera) Doxepin (Silenor) Baclofen (Gablofen; Lioresal) Droperidol (No Brand Name) Benzphetamine (Didrex; Regimex) Duloxetine (Cymbalta) Benztropine (Cogentin) Entacapone (Comtan) Bismuth Ergotamine and caffeine (Cafergot; subcitrate/metronidazole/tetracycline Migergot) (Pylera) Escitalopram (Lexapro) Bismuth subsalicylate (Pepto-Bismol) Fluoxetine (Prozac; Sarafem)
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Utah Medicaid Pharmacy and Therapeutics Committee Drug
    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Single Ingredient Nasal Corticosteroids Beclomethasone dipropionate (Qnasl) Beclomethasone dipropionate monohydrate (Beconase AQ) Budesonide (Rhinocort) Ciclesonide (Omnaris, Zetonna) Flunisolide (Generic) Fluticasone Furoate (Flonase Sensimist) Fluticasone Propionate (Flonase, Xhance) Mometasone Furoate (Nasonex) Triamcinolone Acetonide (Nasacort) AHFS Classification: 52.08.08 Corticosteroids (EENT) Final Report February 2018 Review prepared by: Valerie Gonzales, Pharm.D., Clinical Pharmacist Elena Martinez Alonso, B.Pharm., MSc MTSI, Medical Writer Vicki Frydrych, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Research Assistant Professor Joanne LaFleur, Pharm.D., MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved Contents Abbreviations ................................................................................................................................................ 2 Executive Summary ....................................................................................................................................... 3 Introduction .................................................................................................................................................. 5 Table 1. Nasal corticosteroid products .............................................................................................
    [Show full text]
  • Drug Class Review Nasal Corticosteroids
    Drug Class Review Nasal Corticosteroids Final Report Update 1 June 2008 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Dana Selover, MD Tracy Dana, MLS Colleen Smith, PharmD Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Marian McDonagh, PharmD, Principal Investigator, Drug Effectiveness Review Project Copyright © 2008 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 1 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION ..........................................................................................................................5 Scope and Key Questions .......................................................................................................................7 METHODS ....................................................................................................................................9 Literature Search .....................................................................................................................................9
    [Show full text]
  • Formulary (List of Covered Drugs)
    2018 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN Assurance Rx (HMO-POS) Essence Rx (HMO-POS) Esteem Rx (HMO-POS) Promise Rx (HMO-POS) Spirit Rx (HMO-POS) Surety Rx (HMO-POS) This formulary was updated on Nov. 21, 2018. For more recent information or other questions, please contact Security Health Plan Customer Service at 1-877-998-0998 or, for TTY users, 711, or visit https://www.securityhealth.org/medicareformulary. We are open 7 days a week, 8 a.m. to 8 p.m., from Oct. 1-March 31; and Monday through Friday, 8 a.m. to 8 p.m., from April 1-Sept. 30. Y0117_MC-778-0628-C-09-18 Effective date 12/1/2018 Updated 11/21/2018 Formulary ID 00018450, v.20 Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us,” or “our,” it means Security Health Plan. When it refers to “plan” or “our plan,” it means Assurance Rx (HMO-POS), Essence Rx (HMO-POS), Promise Rx (HMO-POS), Spirit Rx (HMO- POS) or Surety Rx (HMO-POS). This document includes a list of the drugs (formulary) for our plan which is current as of Dec. 1, 2018. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit.
    [Show full text]
  • Use of Amitriptyline for the Treatment of Chronic Tension-Type Headache
    Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E567-72. Amitriptyline and chronic tension-type headache Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E567-72. Amitriptyline and chronic tension-type headache Publication Types: Review Use of amitriptyline for the treatment of chronic tension-type headache. Review of the literature Eulalia Torrente Castells 1, Eduardo Vázquez Delgado 2, Cosme Gay Escoda 3 (1) Odontóloga. Residente del Máster de Cirugía Bucal e Implantología Bucofacial. Facultad de Odontología de la Universidad de Barcelona (2) Odontólogo. Profesor Asociado de Cirugía Bucal. Profesor responsable de la Unidad de Patología de la ATM y Dolor Bucofacial del Máster de Cirugía Bucal e Implantología Bucofacial. Facultad de Odontología de la Universidad de Barcelona. Especialista de la Unidad de Patología de la ATM y Dolor Bucofacial del Centro Médico Teknon. Barcelona (3) Médico-Estomatólogo y Cirujano Maxilofacial. Catedrático de Patología Quirúrgica Bucal y Maxilofacial. Director del Máster de Cirugía Bucal e Implantología Bucofacial. Facultad de Odontología de la Universidad de Barcelona. Co-director de la Unidad de Patología de la ATM y Dolor Bucofacial del Centro Médico Teknon. Barcelona Correspondence: Prof. Cosme Gay Escoda Centro Médico Teknon C/Vilana nº 12 08022 Barcelona E-mail: [email protected] Torrente-Castells E, Vázquez-Delgado E, Gay-Escoda C. Use of amitrip- Received: 28/09/2007 tyline for the treatment of chronic tension-type headache. Review of the Accepted: 11/07/2008 literature. Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E567-72. © Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946 Indexed in: http://www.medicinaoral.com/medoralfree01/v13i9/medoralv13i9p567.pdf -Index Medicus / MEDLINE / PubMed -EMBASE, Excerpta Medica -SCOPUS -Indice Médico Español -IBECS Abstract Amitriptyline is a tricyclic antidepressant, considered the treatment of choice for different types of chronic pain, including chronic myofascial pain.
    [Show full text]
  • Pharmaceuticals and Medical Devices Safety Information No
    Pharmaceuticals and Medical Devices Safety Information No. 242 December 2007 Table of Contents 1. Important Safety Information ·························································3 .1. Atorvastatin Calcium Hydrate ······························································3 .2. Tizanidine Hydrochloride ····································································· 6 .3. Thiamazole ··························································································8 2. Revision of PRECAUTIONS (No. 192) Amitriptyline Hydrochloride and 11 others·······································13 3. List of products subject to Early Post-marketing Phase Vigilance ·········································································································· 21 This Pharmaceuticals and Medical Devices Safety Information (PMDSI) is issued based on safety information collected by the Ministry of Health, Labour and Welfare. It is intended to facilitate safer use of pharmaceuticals and medical devices by healthcare providers. PMDSI is available on the Pharmaceuticals and Medical Devices Agency website (http://www.pmda.go.jp/english/index.html) and on the MHLW website (http://www.mhlw.go.jp/) (Japanese only). Published by Translated by Pharmaceutical and Food Safety Bureau, Pharmaceuticals and Medical Devices Agency Ministry of Health, Labour and Welfare Pharmaceutical and Food Safety Bureau, Office of Safety, Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency 1-2-2 Kasumigaseki, Chiyoda-ku,
    [Show full text]
  • Alternatives to the Most-Prescribed HMSA High-Risk Medication (HRM) List 2018 Items in Bold Are on the 2018 HMSA Formulary
    Alternatives to the Most-prescribed HMSA High-risk Medication (HRM) List 2018 Items in bold are on the 2018 HMSA formulary. Drugs to Avoid Concern Possible Alternatives eszopiclone Cognitive impairment, delirium, unsteady gait, Nonpharmacologic therapy (e.g., avoid daytime naps and caffeinated zolpidem syncope, falls, motor vehicle accidents, beverages, and other sleep hygiene techniques), assess for treatment zaleplon fractures, sleep behaviors, and anterograde for depression and anxiety. amnesia with minimal improvement in sleep latency and duration. methyldopa High risk of adverse CNS effects; may cause Consider thiazide diuretics (HCTZ, indapamide, metolazone); ACEI bradycardia and orthostatic hypotension. (benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril, ramipril, trandolapril); ARBs (irbesartan, losartan, valsartan); long- digoxin In heart failure, high dosages are associated acting dihydropyridine calcium channel blockers (amlodipine, >0.125 mg/day with no additional benefit; decreased clearance felodipine, nifedipine ER). may lead to risk of toxic effects. Consider rate control before rhythm control; monitor SCr and digoxin levels (free digoxin level). nitrofurantoin Potential for pulmonary toxicity; hepatotoxicity For uncomplicated cystitis: trimethoprim or TMP-SMX. Consider and peripheral neuropathy with long-term use. patient's allergy history, renal adjustment, and other risk factors and local Avoid in patients with CrCl <30 mL/min due to resistance patterns. inadequate drug concentration in the urine. amitriptyline Highly anticholinergic, (i.e., constipation, dry For depression: SSRI (citalopram, escitalopram, fluoxetine, clomipramine mouth), cognitive impairment, delirium, sedation sertraline), SNRI (desvenlafaxine, duloxetine, venlafaxine), or others doxepin >6 mg/day orthostatic hypotension. (buproprion, mirtazapine) can be selected based on adverse effect imipramine profiles, cost, and patient preferences. For neuropathic pain: gabapentin, duloxetine, pregabalin.
    [Show full text]